Outpatient Bispecifics: Keeping Myeloma Patients Out of the Hospital | IMS 2026 #myeloma

Andrew Kowalski, PharmD, of University of Miami Sylvester Comprehensive Cancer Center discusses his team's outpatient step-up dosing model for bispecific antibodies at IMS 2026 in Glasgow. Many centers admit patients to the hospital for several days when starting these drugs, which can be a barrier for people who live far away. He explains how a short observation period, preventive tocilizumab and daily telehealth check-ins have kept patients out of the hospital so far, with no CRS readmissions, and how this could expand access.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Timestamps:
0:00 Introduction
0:14 Why outpatient step-up dosing matters
0:32 How the outpatient model works
0:58 Daily telehealth check-ins
1:38 Does preventive tocilizumab have side effects?
2:12 Readmissions for CRS